Trinity Biotech develops, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious diseases, sexually transmitted diseases, blood disorders and autoimmune disorders, as well as monitoring and diagnosing diabetes and hemoglobin variants. The company operates in Ireland, Luxembourg, Canada, Sweden, Brazil, the US, Germany, France and the UK. The company's product portfolio includes: clinical laboratory, point of care products and laboratory services. The clinical laboratory product line includes diagnostic tests and instrumentation for infectious diseases, autoimmune diseases, and hemoglobin. Trinity Biotech manufactures products for niche and specialized applications in infectious diseases. The key disease areas served include lyme disease; sexually transmitted diseases, including syphilis, chlamydia and herpes simplex virus; respiratory infections, including legionella and influenza; Epstein Barr virus; and other viral pathogens, including measles, mumps, rubella and varicella. The company, through Immco Diagnostics, develops, manufactures and distributes products in immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), western blot (WB) and line immunoassay (LIA) formats for diagnosis of autoimmune diseases. The key disease areas served by the Trinity Biotech products include: rheumatoid arthritis, vasculitis, lupus, celiac and Crohn’s disease, ulcerative colitis, neuropathy, Hashimoto’s disease and Grave’s disease. . Trinity Biotech, through Primus Corporation, focuses on products for in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes and Hb Variants for the detection of haemoglobinapothies The company's specialty clinical chemistry business includes reagent products such as ACE, bile acids, lactate, oxalate and glucose six phosphate dehydrogenate (G6PDH). These products are suitable for both manual and automated testing and helps in diagnosing liver disease, kidney disease and G6PDH deficiency which is an indicator of haemolytic anaemia. Trinity Biotech's Point of Care (POC) refers to diagnostic tests, which are carried out in the presence of the patient. Trinity Biotech's range of POC tests principally test for the presence of HIV antibodies. The company's principal product includes UniGold HIV. UniGold HIV is used in public health facilities, hospitals and other outreach facilities. The company also offers a number of products to screen donated blood for transfusion-transmissible infections; and critical time-sensitive diagnostic tests which are performed in emergency rooms, STAT labs, pre/post-operative units, physician office labs (POL's) and the central laboratory. Trinity Biotech provides raw materials to the life sciences industry. Trinity Biotech sells worldwide in over 100 countries through its own sales force and a network of international distributors and strategic partners. Geographically, the company classifies its operations into three segments, namely Americas, Asia/Africa, and Europe (including Ireland). In FY2016, Americas segment accounted for 61.8% of the company's total revenues, followed by Asia/Africa with 25.6%; and Europe (including Ireland) with 12.5%. The company's subsidiaries include Trinity Biotech Manufacturing Limited, Trinity Research Limited, Benen Trading Limited, Trinity Biotech Inc, Clark Laboratories Inc, Fitzgerald Industries International, Primus Corporation and Phoenix Bio-tech Corp.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Trinity Biotech plc in terms of revenue, net income, and operating income.
-- Financials - Details about Trinity Biotech plc listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Trinity Biotech plc’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Trinity Biotech plc’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Trinity Biotech plc’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Trinity Biotech plc operate and what are key points about it?
-- What is the product / service portfolio of Trinity Biotech plc?
-- How has Trinity Biotech plc performed financially from the 2013?
-- How does Trinity Biotech plc rank among its peers in terms of revenue and market share?
-- What are Trinity Biotech plc strengths and weaknesses and what opportunities and threats does it face?
-- What are Trinity Biotech plc’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Trinity Biotech plc? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years